OpenURL Connection Search

Select item for more details and to access through your institution.

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.
Published in:
Bone Marrow Transplantation, 2015, v. 50, n. 8, p. 1057, doi. 10.1038/bmt.2015.82
By:
- Goyal, S D;
- Zhang, M-J;
- Wang, H-L;
- Akpek, G;
- Copelan, E A;
- Freytes, C;
- Gale, R P;
- Hamadani, M;
- Inamoto, Y;
- Kamble, R T;
- Lazarus, H M;
- Marks, D I;
- Nishihori, T;
- Olsson, R F;
- Reshef, R;
- Ritchie, D S;
- Saber, W;
- Savani, B N;
- Seber, A;
- Shea, T C
Publication type:
Article
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
Published in:
Leukemia (08876924), 2015, v. 29, n. 8, p. 1754, doi. 10.1038/leu.2015.75
By:
- Olsson, R F;
- Logan, B R;
- Chaudhury, S;
- Zhu, X;
- Akpek, G;
- Bolwell, B J;
- Bredeson, C N;
- Dvorak, C C;
- Gupta, V;
- Ho, V T;
- Lazarus, H M;
- Marks, D I;
- Ringdén, O T H;
- Pasquini, M C;
- Schriber, J R;
- Cooke, K R
Publication type:
Article
PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).
Published in:
Hematological Oncology, 2023, v. 41, p. 129, doi. 10.1002/hon.3163_87
By:
- Danilov, A.;
- Gregory, G. P.;
- Morschhauser, F.;
- Cheah, C. Y.;
- Shah, H.;
- Jurczak, W.;
- Olabode, D.;
- Meyer, S.;
- Yoon, J. L.;
- Arduini, S.;
- Saeh, J.;
- Olsson, R. F.;
- Strati, P.
Publication type:
Article
Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis.
Published in:
Hematological Oncology, 2023, v. 41, p. 568, doi. 10.1002/hon.3164_425
By:
- Zinzani, P. L.;
- Feldman, T.;
- Collins, G.;
- Zain, J.;
- Khot, A.;
- Kim, J. S.;
- Morschhauser, F.;
- Kim, T. M.;
- Roderick, J.;
- Yoon, J. L.;
- Sharma, S.;
- Saeh, J.;
- Dai, J.;
- Reyes, R.;
- Olsson, R. F.;
- Shortt, J.
Publication type:
Article

Found: 4

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.

Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.

PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL).

Encouraging complete responses (CRs) with CDK9 inhibitor AZD4573 in patients (pts) with relapsed/refractory (r/r) peripheral T‐cell Lymphoma (PTCL): Early trial analysis.